The injection works by mimicking the GLP-1 hormone that is usually produced in the gut and reduces blood glucose levels experienced post meal.
The EU licensing of the drug is based upon the results
The biosimilar had already been approved by the European Commission in November 2017.
Ontruzant would be marketed by Merck & Company in the U.S.
South Korea based Samsung
In an official release, the FDA reiterates support for generics and also encouraged pharma companies to pursue the same, by highlighting branded drugs sans restrictions for generic versions.
The U.S. Food and Drug Administration (
Alphabet’s UK-based health and artificial intelligence company, DeepMind is reportedly merging parts of its business with Google. As per trusted sources, DeepMind’s health subsidiary will shift under Google’s newly formed Google Health team hea
LG Chem, the South Korean chemicals and life sciences company that is also a part of the LG Group, recently announced a partnership with Massachusetts-based drug maker Cue Biopharma.
Swiss pharmaceutical giant Novartis has reportedly announced to have received the approval of Health Canada to use the combination of its two cancer therapies as a targeted treatment to avert recurrence of melanoma.
As per trusted sources, the com
Switzerland based pharmaceutical company Roche Holding AG and AbbVie Inc, a U.S. biopharmaceutical firm, have recently announced that their targeted therapy delayed the growth of a category of blood and bone marrow cancer. Apparently, the therapy was
German pharmaceutical company Grünenthal reportedly announced to have acquired worldwide rights (except the U.S. & Japan) to AstraZeneca’s Vimovo® (naproxen/esomeprazole) and pharma giant’s European rights to Nexium (esomeprazole) for USD 9
Global pharmaceutical company, Eli Lilly and Co. has recently announced a $100 million global licensing and research collaboration with biotechnology firm, Dicerna Pharmaceuticals Inc., making it the latest major drug maker to bet on RNA interference